Traditional Chinese medicine and related active compounds against hepatitis B virus infection

BioScience Trends

Volumn 4, Issue 2, 2010, Pages 39-47

  Cui, Xiaoyan ^a,b   Wang, Yueling ^c   Kokudo, Norihiro ^b   Fang, Dingzhi ^a   Tang, Wei ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF TOKYO   (Japan)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Hepatitis B virus (HBV); Oxymatrine; Phyllanthus; Salvia miltiorrhiza; Traditional Chinese medicine

Indexed keywords

ALKALOID; ANTIVIRUS AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; FLAVANONE DERIVATIVE; HERBACEOUS AGENT; OXYMATRINE; QUINOLIZINE DERIVATIVE; RADIX ASTRAGALI SEU HEDYSARI; WOGONIN;

CHEMICAL STRUCTURE; CHEMISTRY; CHINESE MEDICINE; DRUG EFFECT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; METHODOLOGY; PHYLLANTHUS; PHYTOTHERAPY; REVIEW; RHUBARB; SALVIA MILTIORRHIZA;

ALKALOIDS; ANTIVIRAL AGENTS; ARTEMISININS; DRUGS, CHINESE HERBAL; FLAVANONES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MEDICINE, CHINESE TRADITIONAL; MOLECULAR STRUCTURE; PHYLLANTHUS; PHYTOTHERAPY; QUINOLIZINES; RHEUM; SALVIA MILTIORRHIZA;

EID: 77956893733     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Rokuhara A, Sun X, Tanaka E, Kimura T, Matsumoto A, Yao D, Yin L, Wang N, Maki N, Kiyosawa K. Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection. J Gastroenterol Hepatol. 2005; 20:1726-1730.
2. WHO. WHO position on the use of hepatitis B vaccines. Wkly Epidemiol Rec. 2004; 28:255-263.
3. Ochirbat T, Ali M, Pagbajab N, Erkhembaatar LO, Budbazar E, Sainkhuu N, Tudevdorj E, Kuroiwa C. Assessment of hepatitis B vaccine-induced seroprotection among children 5-10 years old in Ulaanbaatar, Mongolia. Biosci Trends. 2008; 2:68-74.
4. Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharm Res. 2008; 25:72-86.
5. Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY. Fatal submassive hepatic necrosis associated with tyrosinemethionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis. 2001; 33:403-405.
6. Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepatogastroenterology. 1998; 45 Suppl 3:1206-1213.
7. Mehta DH, Gardiner PM, Phillips RS, McCarthy EP. Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med. 2008; 14:1263-1269.
8. McCulloch M, Broffman M, Gao J, Colford JM Jr. Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomized, controlled trials. Am J Public Health. 2002; 92:1619-1627.
9. Kitazato K, Wang YF, Kobayashi N. Viral infectious disease and natural products with antiviral activity. Drug Discov Ther. 2007; 1:14-22.
10. Girish C, Pradhan SC. Drug development for liver diseases: focus on picroliv, ellagic acid and curcumin. Fundam Clin Pharmacol. 2008; 22:623-632.
11. Li AY, Xie YY, Qi FH, Li J, Wang P, Xu SL, Zhao L. Anti-virus effect of traditional Chinese medicine Yi-Fu-Qing granule on acute respiratory tract infections. Biosci Trends. 2009; 3:119-123.
12. Dane DS, Cameron CH, Briggs M. Virus-like particles in the serum of patients with Australia-antigen-associated hepatitis. Lancet. 1970; 1:695-698.
13. Ganem D. Assembly of hepadnaviral virions and subviral particles. Curr Top Microbiol Immunol. 1991; 168:61-83.
14. Robinson WS, Lutwick LI. The virus of hepatitis, type B. N Engl J Med. 1976; 295:1168-1175.
15. Summers J, O'Connell A, Millman I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci U S A. 1975; 72:4597-4601.
16. Chen Y, Wu W, Li LJ, Lou B, Zhang J, Fan J. Comparison of the results for three automated immunoassay systems in determining serum HBV markers. Clin Chim Acta. 2006; 372:129-133.
17. Liu J, McIntosh H, Lin H. Chinese medicinal herbs for chronic hepatitis B: A systematic review. Liver. 2001; 21:280-286.
18. Wang BE. Treatment of chronic liver diseases with traditional Chinese medicine. J Gastroenterol Hepatol. 2000; 15 Suppl:E67-E70.
19. Blumberg BS. Hepatitis B virus: search for plant-derived antiviral. In: Medical Plants - Their Role in Health and Biodiversity (Tomlinson TR, Akerele D, eds.). University of Pennsylvania Press, Philadelphia, PA, USA, 1998; p. 7.
20. Lam WY, Leung KT, Law PT, Lee SM, Chan HL, Fung KP, Ooi VE, Waye MM. Antiviral effect of Phyllanthus nanus ethanolic extract against hepatitis B virus (HBV) by expression microarray analysis. J Cell Biochem. 2006; 97:795-812.
21. Lee CD, Ott M, Thyagarajan SP, Shafritz DA, Burk RD, Gupta S. Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication. Eur J Clin Invest. 1996; 26:1069-1076.
22. Huang ZR, Zhong JP, Zhu GL, Chen YR, Wang GQ. Therapeutic observation on Phyllanthus amarus for hepatitis B. Chin J Clin Hepatol. 1993; 9:108-110. (in Chinese)
23. Liu J, Lin H, McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J Viral Hepat. 2001; 8:358-366.
24. Li CQ, Wang XH, Li GQ, Fang HX. Clinical observation of genus Phyllanthus compound for treatment of chronic hepatitis B. New Traditional Chinese Med. 1998; 30:45. (in Chinese)
25. Zheng XY, Zhou DQ, Gao H, Huang B, Zhou XZ. The clinical study of chronic hepatitis B treated with HBGranule-3. Chinese J Integrated Traditional Western Med Gastro-Spleen. 1999; 7:22-24. (in Chinese)
26. Wang XH, Li CQ, Guo XB, Li H, Lao SX. Clinical observation on 40 cases of chronic hepatitis B treated by Phyllanthus compound combination with interferon. Chinese J Integrated Traditional Western Med Liver Dis. 1999; 9:12-13. (in Chinese)
27. Zhou DQ, Zheng XY. Clinical study on chronic hepatitis B treated by IFN-alpha combination with hepatitis B Granule No. 3. Chinese J Integrated Traditional Western Med Liver Dis. 1999; 9:5-7. (in Chinese)
28. Huang ZR, Zhong JP, Zhu GL, Chen YR, Wang GQ. Therapeutic observation on Phyllanthus amarus for hepatitis B. Chinese J Clin Hepatol. 1993; 9:108-110. (in Chinese)
29. Huang KM. Genus Phyllanthus for treatment of 28 cases of chronic hepatitis B. J Traditional Chinese Med Pharmacol Information. 1999; 16:32. (in Chinese)
30. Cao WZ, Liu JQ, Cao DY, Su F, Xu SG. Clinical study on anti-HBV activity of Phyllanthus herb from Anhui, China. Zhongguo Zhong Yao Za Zhi. 1998; 23: 180-181. (in Chinese)
31. Ma FX, Zhang Y. Clinical observation of compound Phyllanthus amarus for treatment of asymptomatic hepatitis B virus carriers. Shanghai J Traditional Chinese Med. 1993; 27:8-9. (in Chinese)
32. Wang L, Luo SW, Zhang JC, Dong J, Zhang Y. Study on anti-HBV effect of Gankang for the treatment of chronic hepatitis B. Chinese J Integrated Traditional Western Med Liver Dis. 1999; 9:14-15. (in Chinese)
33. Zhang JL, He WN, Ye P. Clinical observation on Phyllanthus amarus for treating chronic hepatitis HBV infection. Chinese J Integrated Traditional Western Med Liver Dis. 1992; 2:8-10. (in Chinese)
34. Zhang JJ, Sun WQ, Wang BX. Yigan Kang Te capsule for treatment of 69 cases of chronic hepatitis B. Chinese J Integrated Traditional Western Med Liver Dis. 1996; 6:33-34. (in Chinese)
35. Zhang JJ, Sun WQ, Yan XS, Wang BX. Clinical observation on genus Phyllanthus compound capsule for treatment of 59 cases of chronic hepatitis B. Pract J Integrated Traditional Chinese Western Medicine. 1997; 10:870-871. (in Chinese)
36. Chan HL, Sung JJ, Fong WF, Chim AM, Yung PP, Hui AY, Fung KP, Leung PC. Double-blinded placebocontrolled study of Phyllanthus urinaris for the treatment of chronic hepatitis B. Aliment Pharmacol Ther. 2003; 18:339-345.
37. Leung SW, Zhu DY, Man RY. Effects of the aqueous extract of Salvia Miltiorrhiza (Danshen) and its magnesium tanshinoate B-enriched form on blood pressure. Phytother Res. 2009 [Epub ahead of print].
38. Zhou Z, Zhang Y, Ding XR, Chen SH, Yang J, Wang XJ, Jia GL, Chen HS, Bo XC, Wang SQ. Protocatechuic aldehyde inhibits hepatitis B virus replication both in vitro and in vivo. Antiviral Res. 2007; 74:59-64.
39. Xiong LL. Therapeutic effect of combined therapy of Salvia Miltiorrhiza and Polyporus Umbellatus Polysaccharide in treating chronic Hepatitis B. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1993; 13:533-535, 516-517. (in Chinese)
40. Zhang AL, Wu Y, Jiang XL. Analysis on therapeutic effect of acupoint-injection on chronic hepatitis B. Zhongguo Zhen Jiu. 2005; 25:25-26. (in Chinese)
41. Wang S, Li J, Huang H, Gao W, Zhuang C, Li B, Zhou P, Kong D. Anti-hepatitis B virus activities of astragaloside IV isolated from Radix Astragali. Biol Pharm Bull. 2009; 32:132-135.
42. Qi LW, Yu QT, Li P, Li SL, Wang YX, Sheng LH, Yi L. Quality evaluation of Radix Astragali through a simultaneous determination of six major active isoflavonoids and four main saponins by highperformance liquid chromatography coupled with diode array and evaporative light scattering detectors. J Chromatogr A. 2006; 1134:162-169.
43. Tang LL, Sheng JF, Xu CH, Liu KZ. Clinical and experimental effectiveness of Astragali compound in the treatment of chronic viral hepatitis B. J Int Med Res. 2009; 37:662-667.
44. Wang J, Zhao H, Kong W, Jin C, Zhao Y, Qu Y, Xiao X. Microcalorimetric assay on the antimicrobial property of five hydroxyanthraquinone derivatives in rhubarb (Rheum palmatum L.) to Bifidobacterium adolescentis. Phytomedicine. 2009 [Epub ahead of print].
45. Hsiang CY, Hsieh CL, Wu SL, Lai IL, Ho TY. Inhibitory effect of anti-pyretic and anti-inflammatory herbs on herpes simplex virus replication. Am J Chin Med. 2001; 29:459-467.
46. Ma Y, Xuan Y, Cao D. Effects of rheum of ficinale baill on cultured rat myocardial cells with infection of coxsackie virus B3. J Pediatr Pharm. 2001; 7:1-3. (in Chinese)
47. Zhang B, Chen J, Li H, Xu X. Study on the Rheum palmatum volatile oil against HBV in cell culture in vitro. Zhong Yao Cai. 1998; 21:524-526. (in Chinese)
48. Kim TG, Kang SY, Jung KK, Kang JH, Lee E, Han HM, Kim SH. Antiviral activities of extracts isolated from Terminalis chebula Retz., Sanguisorba officinalis L., Rubus coreanus Miq. and Rheum palmatum L. against hepatitis B virus. Phytother Res. 2001; 15:718-720.
49. Chung TH, Kim JC, Kim MK, Choi SC, Kim SL, Chung JM, Lee IS, Kim SH, Hahn KS, Lee IP. Investigation of Korean plant extracts for potential phytotherapeutic agents against B-virus hepatitis. Phytother Res. 1995; 9:429-434.
50. Chung TH, Kim JC, Lee CY, Moon MK, Chae SC, Lee IS, Kim SH, Hahn KS, Lee IP. Potential antiviral effects of Sanguisorba officinalis, Terminalis chebula, Rubusanus migua, and Rheum palmatum against duck hepatitis B virus (DHBV). Phytother Res. 1997; 11:179-182.
51. Li Z, Li LJ, Sun Y, Li J. Identification of natural compounds with anti-hepatitis B Virus activity from Rheum palmatum L. ethanol extract. Chemotherapy. 2007; 53:320-326.
52. Wu XN, Wang GJ. Experimental studies of oxymatrine and its mechanisms of action in hepatitis B and C viral infections. Chin J Dig Dis. 2004; 5:12-16.
53. Xu WS, Wang GJ, Miao XH, Cai X. Effect of oxymatrine on expression of hepatitis B virus DNA in HepG2.2.15 cells. Acad J Second Military Med Univ. 2002; 23:72-73. (in Chinese)
54. Chen XS, Wang GJ, Cai X, Yu HY, Hu YP. Inhibition of hepatitis B virus by oxymatrine in vivo. World J Gastroenterol. 2001; 7:49-52.
55. Lu LG, Zeng MD, Mao YM, et al. Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial. World J Gastroenterol. 2003; 9:2480-2483.
56. Xu DX. Effect of oxymatrine capsule on chronic hepatitis B. Occupation and Health. 2008; 24:2. (in Chinese)
57. Lu SS, Wu LO, Yang ZQ. Progress of research on artemisinin in combination with other anti-malarial drugs. Zhongguo Bing Yuan Sheng Wu Xue Za Zhi. 2009; 3:232-235. (in Chinese)
58. Romero MR, Efferth T, Serrano MA, Castaño B, Macias RI, Briz O, Marin JJ. Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. Antiviral Res. 2005; 68:75-83.
59. Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, ter Kuile F, Kham A, Chongsuphajaisiddhi T, White NJ, Nosten F. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg. 1999; 60:547-555.
60. Tai MC, Tsang SY, Chang LY, Xue H. Therapeutic potential of wogonin: A naturally occurring flavonoid. CNS Drug Rev. 2005; 11:141-150.
61. Huang RL, Chen CC, Huang HL, Chang CG, Chen CF, Chang C, Hsieh MT. Anti-hepatitis B virus effects of wogonin isolated from Scutellaria baicalensis. Planta Med. 2000; 66:694-698.
62. Guo QL, Zhao L, You QD, Yang Y, Gu HY, Song GL, Lu N, Xin J. Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res. 2007; 74:16-24.
63. Thyagarajan SP, Jayaram S, Gopalakrishnan V, Hari R, Jeyakumar P, Sripathi MS. Herbal medicines for liver diseases in India. J Gastroenterol Hepatol. 2002; 17 Suppl 3:S370-S376.
64. Chattopadhyay D, Sarkar MC, Chatterjee T, Sharma Dey R, Bag P, Chakraborti S, Khan MT. Recent advancements for the evaluation of anti-viral activities of natural products. N Biotechnol. 2009; 25:347-368.
65. Chen X, Ung CY, Chen Y. Can an in silico drug-target search method be used to probe potential mechanisms of medicinal plant ingredients? Nat Prod Rep. 2003; 20:432-444.
66. Gai RY, Xu HL, Qu XJ, Wang FS, Lou HX, Han JX, Nakata M, Kokudo N, Sugawara Y, Kuroiwa C, Tang W. Dynamic of modernizing traditional Chinese medicine and the standards system for its development. Drug Discov Ther. 2008; 2:2-4.
67. Efferth T, Li PC, Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med. 2007; 13:353-361.
68. Chen X, Zhou H, Liu YB, Wang JF, Li H, Ung CY, Han LY, Cao ZW, Chen YZ. Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation. Br J Pharmacol. 2006; 149:1092-1103.
69. Kang YJ. Herbogenomics: From traditional Chinese medicine to novel therapeutics. Exp Biol Med (Maywood). 2008; 233:1059-1065.
70. Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig Dis Sci. 2005; 50:1807-1812.